Regeneron, Sanofi, get ready to duke it out with Pfizer over a megablockbuster eczema market
Sometime over the next few days or weeks, the FDA will likely hand Regeneron and Sanofi an approval for Dupixent (dupilumab), their groundbreaking IL-4/IL-13 inhibitor for eczema which a number of analysts have projected will go on to grab $4 billion-plus a year in annual sales. And they’ll hit the market with some stellar new 16- and 52-week data from another Phase III study as they go up against Pfizer’s newly approved Eucrisa (crisaborole, targeting PDE4).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.